Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 644

1.

Heart Rate Variability Markers as Correlates of Survival in Recipients of Hematopoietic Cell Transplantation
.

Scheiber C, Johnston L, Packer M, Gevirtz R, Edwards KS, Palesh O.

Oncol Nurs Forum. 2018 Mar 1;45(2):250-259. doi: 10.1188/18.ONF.250-259.

PMID:
29466350
2.

Data sharing in medical research.

Packer M.

BMJ. 2018 Feb 14;360:k510. doi: 10.1136/bmj.k510. No abstract available.

PMID:
29444885
3.

Do Dipeptidyl Peptidase-4 Inhibitors Cause Heart Failure Events by Promoting Adrenergically-Mediated Cardiotoxicity? Clues from Laboratory Models and Clinical Trials.

Packer M.

Circ Res. 2018 Feb 7. pii: CIRCRESAHA.118.312673. doi: 10.1161/CIRCRESAHA.118.312673. [Epub ahead of print]

PMID:
29436388
4.

Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).

Mogensen UM, Gong J, Jhund PS, Shen L, Køber L, Desai AS, Lefkowitz MP, Packer M, Rouleau JL, Solomon SD, Claggett BL, Swedberg K, Zile MR, Mueller-Velten G, McMurray JJV.

Eur J Heart Fail. 2018 Feb 12. doi: 10.1002/ejhf.1139. [Epub ahead of print]

PMID:
29431251
5.

Are physicians neglecting the risk of heart failure in diabetic patients who are receiving sulfonylureas? Lessons from the TOSCA.IT trial.

Packer M.

Eur J Heart Fail. 2018 Jan;20(1):49-51. doi: 10.1002/ejhf.1093. No abstract available.

PMID:
29388338
6.
7.
9.

Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?

Packer M.

Am J Med. 2018 Jan 5. pii: S0002-9343(17)31296-2. doi: 10.1016/j.amjmed.2017.11.052. [Epub ahead of print] No abstract available.

PMID:
29309741
10.

Is the Popularity of Dipeptidyl-Peptidase-4 Inhibitors Justified? Insights From Mechanistic Studies and Clinical Trials.

Packer M.

Am J Med. 2018 Jan 4. pii: S0002-9343(17)31299-8. doi: 10.1016/j.amjmed.2017.11.055. [Epub ahead of print] No abstract available.

PMID:
29307538
11.

Does Neprilysin Inhibition Potentiate or Minimize the Adverse Effects of Glucagon-Like Peptide-1 Receptor Agonists in Chronic Heart Failure?

Packer M.

J Card Fail. 2018 Feb;24(2):109-111. doi: 10.1016/j.cardfail.2017.12.007. Epub 2018 Jan 3. No abstract available.

PMID:
29305970
12.

The Future Treatment of Heart Failure?

Packer M.

Eur Heart J. 2018 Jan 1;39(1):5-7. doi: 10.1093/eurheartj/ehx745. No abstract available.

PMID:
29300940
13.

Acute Heart Failure Is an Event Rather Than a Disease: Plea for a Radical Change in Thinking and in Therapeutic Drug Development.

Packer M.

JACC Heart Fail. 2018 Jan;6(1):73-75. doi: 10.1016/j.jchf.2017.05.008. Review. No abstract available.

PMID:
29284579
14.

Is metformin beneficial for heart failure in patients with type 2 diabetes?

Packer M.

Diabetes Res Clin Pract. 2018 Feb;136:168-170. doi: 10.1016/j.diabres.2017.12.011. Epub 2017 Dec 24.

PMID:
29278713
15.

Heart Failure: The Most Important, Preventable, and Treatable Cardiovascular Complication of Type 2 Diabetes.

Packer M.

Diabetes Care. 2018 Jan;41(1):11-13. doi: 10.2337/dci17-0052. No abstract available.

PMID:
29263193
16.

Absence of an Ideal Observer II: The Agonizing Search for Experts Without a Conflict of Interest.

Packer M.

Circulation. 2017 Dec 19;136(25):2400-2402. doi: 10.1161/CIRCULATIONAHA.117.031200. No abstract available.

PMID:
29255120
17.

Role of the sodium-hydrogen exchanger in mediating the renal effects of drugs commonly used in the treatment of type 2 diabetes.

Packer M.

Diabetes Obes Metab. 2017 Dec 11. doi: 10.1111/dom.13191. [Epub ahead of print] Review.

PMID:
29227582
18.

Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF.

Mogensen UM, Køber L, Jhund PS, Desai AS, Senni M, Kristensen SL, Dukát A, Chen CH, Ramires F, Lefkowitz MP, Prescott MF, Shi VC, Rouleau JL, Solomon SD, Swedberg K, Packer M, McMurray JJV; PARADIGM-HF Investigators and Committees.

Eur J Heart Fail. 2017 Nov 30. doi: 10.1002/ejhf.1056. [Epub ahead of print]

PMID:
29193563
19.

Role of Payers in the Development of Cardiovascular Therapeutics: Misalignment Between Approval and Reimbursement.

Zannad F, Alonso Garcia MLA, Borer JS, Stough WG, Clutton-Brock T, Rosenberg Y, Packer M.

J Am Coll Cardiol. 2017 Dec 5;70(22):2822-2830. doi: 10.1016/j.jacc.2017.10.027. Review.

PMID:
29191332
20.

Are Meta-Analyses a Form of Medical Fake News? Thoughts About How They Should Contribute to Medical Science and Practice.

Packer M.

Circulation. 2017 Nov 28;136(22):2097-2099. doi: 10.1161/CIRCULATIONAHA.117.030209. No abstract available.

PMID:
29180491
21.

Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage.

Gaudelli NM, Komor AC, Rees HA, Packer MS, Badran AH, Bryson DI, Liu DR.

Nature. 2017 Nov 23;551(7681):464-471. doi: 10.1038/nature24644. Epub 2017 Oct 25.

PMID:
29160308
22.

Correction to "Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors".

Johannes JW, Bates S, Beigie C, Belmonte MA, Breen J, Cao S, Centrella PA, Clark MA, Cuozzo JW, Dumelin CE, Ferguson AD, Habeshian S, Hargreaves D, Joubran C, Kazmirski S, Keefe AD, Lamb ML, Lan H, Li Y, Ma H, Mlynarski S, Packer MJ, Rawlins PB, Robbins DW, Shen H, Sigel EA, Soutter HH, Su N, Troast DM, Wang H, Wickson KF, Wu C, Zhang Y, Zhao Q, Zheng X, Hird AW.

ACS Med Chem Lett. 2017 Oct 18;8(11):1204. doi: 10.1021/acsmedchemlett.7b00397. eCollection 2017 Nov 9.

23.

Type of Atrial Fibrillation and Outcomes in Patients With Heart Failure and Reduced Ejection Fraction.

Mogensen UM, Jhund PS, Abraham WT, Desai AS, Dickstein K, Packer M, Rouleau JL, Solomon SD, Swedberg K, Zile MR, Køber L, McMurray JJV; PARADIGM-HF and ATMOSPHERE Investigators and Committees.

J Am Coll Cardiol. 2017 Nov 14;70(20):2490-2500. doi: 10.1016/j.jacc.2017.09.027.

24.

Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy.

Shen L, Ramires F, Martinez F, Bodanese LC, Echeverría LE, Gómez EA, Abraham WT, Dickstein K, Køber L, Packer M, Rouleau JL, Solomon SD, Swedberg K, Zile MR, Jhund PS, Gimpelewicz CR, McMurray JJV; PARADIGM-HF and ATMOSPHERE Investigators and Committees.

Circ Heart Fail. 2017 Nov;10(11). pii: e004361. doi: 10.1161/CIRCHEARTFAILURE.117.004361.

PMID:
29141857
25.
26.

The Imminent Demise of Cardiovascular Drug Development.

Packer M.

JAMA Cardiol. 2017 Dec 1;2(12):1293-1294. doi: 10.1001/jamacardio.2017.3753. No abstract available.

PMID:
29117286
27.

Early Worsening of Renal Function After Treatment with Antihyperglycemic Drugs: A Consistent Finding in Large-Scale Trials.

Packer M.

Am J Med. 2017 Nov 28. pii: S0002-9343(17)31096-3. doi: 10.1016/j.amjmed.2017.10.020. [Epub ahead of print] No abstract available.

PMID:
29106976
28.

Heart Failure With a Mid-Range Ejection Fraction: A Disorder That a Psychiatrist Would Love.

Packer M.

JACC Heart Fail. 2017 Nov;5(11):805-807. doi: 10.1016/j.jchf.2017.08.012. Review. No abstract available.

PMID:
29096788
29.

Will long-acting glucagon-like peptide-1 analogues recapitulate our agonizing experience with cyclic AMP-dependent positive inotropic agents in heart failure?

Packer M.

Eur J Heart Fail. 2017 Oct 30. doi: 10.1002/ejhf.1047. [Epub ahead of print] No abstract available.

PMID:
29082598
30.

Why is the use of digitalis withering? Another reason that we need medical heart failure specialists.

Packer M.

Eur J Heart Fail. 2017 Oct 19. doi: 10.1002/ejhf.1043. [Epub ahead of print] No abstract available.

PMID:
29052294
31.

Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials.

Cleland JGF, Bunting KV, Flather MD, Altman DG, Holmes J, Coats AJS, Manzano L, McMurray JJV, Ruschitzka F, van Veldhuisen DJ, von Lueder TG, Böhm M, Andersson B, Kjekshus J, Packer M, Rigby AS, Rosano G, Wedel H, Hjalmarson Å, Wikstrand J, Kotecha D; Beta-blockers in Heart Failure Collaborative Group.

Eur Heart J. 2018 Jan 1;39(1):26-35. doi: 10.1093/eurheartj/ehx564.

PMID:
29040525
32.

Phage-assisted continuous evolution of proteases with altered substrate specificity.

Packer MS, Rees HA, Liu DR.

Nat Commun. 2017 Oct 16;8(1):956. doi: 10.1038/s41467-017-01055-9.

33.
34.

Is the Way to Someone's Heart Through Their Stomach? The Cardiorenal Paradox of Incretin-Based Hypoglycemic Drugs in Heart Failure.

Packer M.

Circ Heart Fail. 2017 Oct;10(10). pii: e004551. doi: 10.1161/CIRCHEARTFAILURE.117.004551. No abstract available.

PMID:
29021350
35.

Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation.

Kristensen SL, Jhund PS, Mogensen UM, Rørth R, Abraham WT, Desai A, Dickstein K, Rouleau JL, Zile MR, Swedberg K, Packer M, Solomon SD, Køber L, McMurray JJV; PARADIGM-HF and ATMOSPHERE Committees and Investigators.

Circ Heart Fail. 2017 Oct;10(10). pii: e004409. doi: 10.1161/CIRCHEARTFAILURE.117.004409.

PMID:
29018174
36.

The Biological Basis of Chronic Traumatic Encephalopathy following Blast Injury: A Literature Review.

Aldag M, Armstrong RC, Bandak F, Bellgowan PSF, Bentley T, Biggerstaff S, Caravelli K, Cmarik J, Crowder A, DeGraba TJ, Dittmer TA, Ellenbogen RG, Greene C, Gupta RK, Hicks R, Hoffman S, Latta RC 3rd, Leggieri MJ Jr, Marion D, Mazzoli R, McCrea M, O'Donnell J, Packer M, Petro JB, Rasmussen TE, Sammons-Jackson W, Shoge R, Tepe V, Tremaine LA, Zheng J.

J Neurotrauma. 2017 Sep;34(S1):S26-S43. doi: 10.1089/neu.2017.5218.

PMID:
28937953
37.

The Absence of an Ideal Observer: Why Some Clinical Trials May Not Be What We Think They Are.

Packer M.

Circulation. 2017 Sep 19;136(12):1085-1086. doi: 10.1161/CIRCULATIONAHA.117.029700. No abstract available.

PMID:
28923903
38.

How have millions of people with heart failure benefited from our research over the last 10-15 years? The sounds of dead silence.

Packer M.

Eur J Heart Fail. 2017 Nov;19(11):1353-1354. doi: 10.1002/ejhf.935. Epub 2017 Sep 10. No abstract available.

PMID:
28891189
39.

Improved base excision repair inhibition and bacteriophage Mu Gam protein yields C:G-to-T:A base editors with higher efficiency and product purity.

Komor AC, Zhao KT, Packer MS, Gaudelli NM, Waterbury AL, Koblan LW, Kim YB, Badran AH, Liu DR.

Sci Adv. 2017 Aug 30;3(8):eaao4774. doi: 10.1126/sciadv.aao4774. eCollection 2017 Aug.

40.

Human Y-Family DNA Polymerase κ Is More Tolerant to Changes in Its Active Site Loop than Its Ortholog Escherichia coli DinB.

Antczak NM, Packer MR, Lu X, Zhang K, Beuning PJ.

Chem Res Toxicol. 2017 Nov 20;30(11):2002-2012. doi: 10.1021/acs.chemrestox.7b00175. Epub 2017 Sep 6.

PMID:
28823149
41.

Health-Related Quality of Life Outcomes in PARADIGM-HF.

Lewis EF, Claggett BL, McMurray JJV, Packer M, Lefkowitz MP, Rouleau JL, Liu J, Shi VC, Zile MR, Desai AS, Solomon SD, Swedberg K.

Circ Heart Fail. 2017 Aug;10(8). pii: e003430. doi: 10.1161/CIRCHEARTFAILURE.116.003430.

PMID:
28784687
42.

Who Should Deliver Medical Therapy for Patients With Chronic Heart Failure? An Immediate Call for Action to Implement a Community-Based Collaborative Solution.

Packer M.

Circ Heart Fail. 2017 Aug;10(8). pii: e004332. doi: 10.1161/CIRCHEARTFAILURE.117.004332. No abstract available.

PMID:
28775116
43.

Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action.

Packer M, Anker SD, Butler J, Filippatos G, Zannad F.

JAMA Cardiol. 2017 Sep 1;2(9):1025-1029. doi: 10.1001/jamacardio.2017.2275.

PMID:
28768320
44.

Why Has a Run-In Period Been a Design Element in Most Landmark Clinical Trials? Analysis of the Critical Role of Run-In Periods in Drug Development.

Packer M.

J Card Fail. 2017 Sep;23(9):697-699. doi: 10.1016/j.cardfail.2017.07.401. Epub 2017 Jul 28.

PMID:
28760644
45.

Declining Risk of Sudden Death in Heart Failure.

Shen L, Jhund PS, Petrie MC, Claggett BL, Barlera S, Cleland JGF, Dargie HJ, Granger CB, Kjekshus J, Køber L, Latini R, Maggioni AP, Packer M, Pitt B, Solomon SD, Swedberg K, Tavazzi L, Wikstrand J, Zannad F, Zile MR, McMurray JJV.

N Engl J Med. 2017 Jul 6;377(1):41-51. doi: 10.1056/NEJMoa1609758.

46.

Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.

Solomon SD, Rizkala AR, Gong J, Wang W, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, Van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Shi VC, Lefkowitz MP, McMurray JJV.

JACC Heart Fail. 2017 Jul;5(7):471-482. doi: 10.1016/j.jchf.2017.04.013. Epub 2017 Jun 26. Review.

PMID:
28662936
47.

Relationship between subjective and actigraphy-measured sleep in 237 patients with metastatic colorectal cancer.

Palesh O, Haitz K, Lévi F, Bjarnason GA, Deguzman C, Alizeh I, Ulusakarya A, Packer MM, Innominato PF.

Qual Life Res. 2017 Oct;26(10):2783-2791. doi: 10.1007/s11136-017-1617-2. Epub 2017 Jun 27.

PMID:
28656534
48.

Dental education: Potentially damaging disconnect.

Cabot L, Woolford M, Banerjee A, Cobourne M, Hasan A, Lewis-Greene H, Packer M, Sood S, Turner J, Whaites E.

Br Dent J. 2017 Jun 23;222(12):909. doi: 10.1038/sj.bdj.2017.520. No abstract available.

PMID:
28642540
49.

Response by Dr Packer to the Letter of Dr Blankfield.

Packer M.

J Cardiovasc Pharmacol Ther. 2018 Jan;23(1):99-100. doi: 10.1177/1074248417715002. Epub 2017 Jun 22. No abstract available.

PMID:
28639456
50.

Should recommendations for clinical use be restricted to patients who were enrolled in a pivotal clinical trial?

Packer M.

Eur J Heart Fail. 2017 Jun;19(6):779-781. doi: 10.1002/ejhf.816. No abstract available.

PMID:
28586536

Supplemental Content

Loading ...
Support Center